
Shares of transdermal pharma products maker Nutriband NTRB.O rise 3.5% to $7.38
Nutriband says FDA grants meeting request for co's fentanyl patch
The meeting is scheduled for September 18 in which the regulator will provide feedback on co's marketing application for fentanyl patch
NTRB is developing Aversa, a proprietary technology that makes transdermal patches safer by preventing abuse and misuse of potent opioids like fentanyl
Including session moves, stock up 52.44% YTD